Linnaeus Venture’s portfolio company Core-Oli-T AB has completed two funding rounds during 2026, raising a total of SEK 2.5 million from private investors.
Core-Oli-T is a research-based company originating from Linnaeus University, developing antibody-based technology with the potential to enable earlier diagnosis of Parkinson’s disease and, in the longer term, new treatment options.
The new funding strengthens the company’s ability to advance its development activities, focusing on antibody development, intellectual property protection, and upcoming validation studies.
Core-Oli-T is part of Linnaeus Venture’s investment portfolio. The funding marks an important milestone in the company’s development and demonstrates how research-based innovations from Linnaeus University can attract private capital and progress towards commercial applications.
